Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/122777
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartí Coma-Cros, Elisabet-
dc.contributor.authorBiosca, Arnau-
dc.contributor.authorLantero, Elena-
dc.contributor.authorManca, Maria Letizia-
dc.contributor.authorCaddeo, Carla-
dc.contributor.authorGutiérrez, Lucía-
dc.contributor.authorRamírez, Miriam-
dc.contributor.authorBorgheti Cardoso, Livia Neves-
dc.contributor.authorManconi, Maria-
dc.contributor.authorFernàndez Busquets, Xavier-
dc.date.accessioned2018-06-05T07:19:16Z-
dc.date.available2018-06-05T07:19:16Z-
dc.date.issued2018-05-04-
dc.identifier.issn1422-0067-
dc.identifier.urihttp://hdl.handle.net/2445/122777-
dc.description.abstractCurcumin is an antimalarial compound easy to obtain and inexpensive, having shown little toxicity across a diverse population. However, the clinical use of this interesting polyphenol has been hampered by its poor oral absorption, extremely low aqueous solubility and rapid metabolism. In this study, we have used the anionic copolymer Eudragit(®) S100 to assemble liposomes incorporating curcumin and containing either hyaluronan (Eudragit-hyaluronan liposomes) or the water-soluble dextrin Nutriose(®) FM06 (Eudragit-nutriosomes). Upon oral administration of the rehydrated freeze-dried nanosystems administered at 25/75 mg curcumin·kg(−1)·day(−1), only Eudragit-nutriosomes improved the in vivo antimalarial activity of curcumin in a dose-dependent manner, by enhancing the survival of all Plasmodium yoelii-infected mice up to 11/11 days, as compared to 6/7 days upon administration of an equal dose of the free compound. On the other hand, animals treated with curcumin incorporated in Eudragit-hyaluronan liposomes did not live longer than the controls, a result consistent with the lower stability of this formulation after reconstitution. Polymer-lipid nanovesicles hold promise for their development into systems for the oral delivery of curcumin-based antimalarial therapies.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.3390/ijms19051361-
dc.relation.ispartofInternational Journal of Molecular Sciences, 2018, vol. 19, num. 5, p. E1361-
dc.relation.urihttp://dx.doi.org/10.3390/ijms19051361-
dc.rightscc by (c) Martí Coma Cros et al., 2018-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/-
dc.sourceArticles publicats en revistes (ISGlobal)-
dc.subject.classificationMalària-
dc.subject.classificationNanomedicina-
dc.subject.otherMalaria-
dc.subject.otherNanomedicine-
dc.titleAntimalarial Activity of Orally Administered Curcumin Incorporated in Eudragit((R))-Containing Liposomes-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2018-05-23T17:59:35Z-
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/712754/EU//BEST-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid29734652-
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))
Publicacions de projectes de recerca finançats per la UE

Files in This Item:
File Description SizeFormat 
marticoma-cros2018_3041.pdf1.18 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons